Chronic Inducible Urticaria Treatment Market Size, Share & Industry Analysis, By Drug Class (Antihistamines, Monoclonal Antibodies, Antidepressants, Immunosuppressant, and Others), By Indication (Dermographism, Cold Urticaria, Contact Urticaria, Solar Urticaria, and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospitals Pharmacy, Drug Store and Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2026-2034

The global chronic inducible urticaria treatment market is witnessing significant growth due to the rise in awareness of urticaria through awareness campaigns and government initiatives. This growing awareness leads to an increased diagnosis rate, resulting in an increasing number of patients seeking medical attention for this condition. Additionally, emphasis on research & development activities by operating players also supports the market growth. 

• For instance, in October 2023, Jasper Therapeutics, Inc. announced that the U.S. FDA provided clearance to the investigational new drug (IND) application for a Phase 1b/2a repeat dose of briquilimab, for the treatment of chronic spontaneous urticaria (CSU). They intended to start clinical studies of briquilimab as a primary treatment for chronic inducible urticaria (CIndU).

Chronic inducible urticaria (CIndU) is a type of chronic urticaria (hives) where red patches and swelling are triggered by factors, such as exercise, scratching of the skin, and emotional upsets. Heat, cold, sunlight, and contact with water or chemicals are the less common factors that trigger this disease.

Chronic Inducible Urticaria Treatment Market Driver

Rise in Awareness of Chronic Inducible Urticaria Drives Market Growth

The increase in awareness of chronic inducible urticaria through campaigns and government initiatives is driving the market growth. This rise in awareness leads to an increase in focus on early detection and treatment, which ultimately boosts the market growth during the forecast period. Additionally, various organizations, such as the Canadian Chronic Urticaria Society, are working on creating awareness regarding the disease, which is also expected to boost the market growth.

• For instance, according to the data published by the Canadian Chronic Urticaria Society, in October 2024, every year, October 1st is celebrated as World Urticaria Day, which aims to increase awareness about urticaria.

Global Prevalence of Chronic Inducible Urticaria in Adults and Children, 2021

According to the data published by the World Allergy Organization Journal in June 2021, symptomatic dermographism has the highest prevalence in both adults and children, followed by cold urticaria and delayed pressure urticaria.

Chronic Inducible Urticaria Treatment Market Restraint

High Cost of Treatment May Hinder Market Growth

The high cost of treating chronic inducible urticaria (CIU), especially with the newer biologics, significantly hinders the market growth. This is due to the high treatment cost may limit access and adherence for patients with low to moderate incomes. It also leads to a delay in the patients' treatment, which can worsen their condition and potentially increase the overall cost of care in the long run.

• For instance, according to the data published by the National Center for Biotechnology Information, in January 2025, the cost of an inducible urticaria challenge test is high in Colombia, which is USD 112.0.

Chronic Inducible Urticaria Treatment Market Opportunity

Advancements in Existing Treatment Regimens to Offer Growth Opportunity in Future

Currently, only symptomatic treatments for chronic induced urticaria (CIndU) are available, with no standard approvals that target the root cause of this disease. A personalized approach, such as diagnosis based on patient history and provocation testing, would help in the development of innovative treatment. This is expected to offer lucrative growth opportunities in the future. Additionally, a better understanding of the disease may help to develop advanced treatment options, resulting in the development of novel therapies with high efficacy and safety, which may further boost the market growth. 

• For instance, according to the data published by the National Center for Biotechnology Information in August 2019, Omalizumab is being used for the treatment of chronic spontaneous urticaria (CSU). However, its application should be explored for chronic inducible urticariain children younger than 12 years.

Key Insights

The report covers the following key insights:

• Epidemiology of Chronic Inducible Urticaria, By Key Countries, 2024
• Overview of Current Treatment Regimen for Chronic Inducible Urticaria
• New Product Launches, By Key Players
• Key Industry Development (Mergers, Acquisitions, and Partnerships) 

Segmentation

Analysis by Drug Class

By drug class, the market is divided into antihistamines, monoclonal antibodies, antidepressants, immunosuppressants, and others.

The antihistamines segment held a substantial share of the market. The antihistamines are the first-line and most common treatment for chronic inducible urticaria (CIU). Additionally, it is a well-tolerated standard dose and is able to target histamine effectively, as histamine is a key mediator that is released from mast cells after exposure to specific triggers. The observational studies and investigational research studies are expected to boost the growth of this segment. 

• For instance, in May 2024, Novartis AG announced the new data from a phase 3 study, which confirmed the long-term efficacy and safety of remibrutinib, an antihistamine for the treatment of chronic spontaneous urticaria. It is also being investigated in chronic inducible urticaria.

Analysis by Indication

On the basis of indication, the market is further segmented into dermographism, cold urticaria, contact urticaria, solar urticaria, and others. The dermatographism segment is expected to grow significantly during the forecast period. This is due to the fact that it is a common type of inducible urticaria, and it occurs naturally.

• For instance, according to the data published by the National Center for Biotechnology Information, in February 2023, the most common type of inducible urticaria is dermographism, which affects approximately 2% to 5% of the population.

Analysis by Route of Administration

Based on the route of administration, the market is further segmented into oral, parenteral, and topical.

The oral segment held a substantial share of the market in 2024. This is due to the widespread availability of oral medications through various distribution channels and their effectiveness in treating the disease. Additionally, the oral route is convenient and has high patient adherence. The oral antihistamines are the first-line treatment for chronic inducible urticaria, which also support the segment growth. 

• For instance, desloratadine, an oral tablet, is used for the treatment of chronic inducible urticaria in patients 6 months of age and older.

Analysis by Distribution Channel

In terms of distribution channel, the market is divided into hospitals pharmacy, drug store and retail pharmacy, and online pharmacy.

The drug store and retail pharmacy segment held a considerable share of the market. The growth of the segment is attributed to the established distribution network and widespread availability of OTC medications, such as antihistamines, through these distribution channels.

• For instance, the drugs that are used for the treatment of chronic inducible urticaria are easily available through drug stores and retail pharmacies in the form of OTC medications.

By Region

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the global chronic inducible urticaria treatment market in 2024. This is due to the strong presence of key market players, who are actively involved in the development of new treatment options for chronic induced urticaria. Additionally, supportive reimbursement policies in the region, which increase the patient adherence rate, further result in high product usage. This supports the market growth in this region during the forecast period.

• For instance, in February 2025, Jasper Therapeutics, Inc. announced the Briquilimab data from the phase 1b/2a study at the annual meeting of the American Academy of Dermatology (AAD). Briquilimab is a novel antibody therapy targeting to address mast cell-induced chronic diseases such as chronic induced urticaria (CIndU).

Europe held a considerable share of the chronic inducible urticaria treatment market. The growth of the region is due to the rising awareness and product availability for chronic inducible urticaria. The European Commission (EC) has granted approval for omalizumab for the treatment of chronic spontaneous urticaria (CSU). However, omalizumab is also used as an off-label drug for the treatment of chronic inducible urticaria. The increase in the disease burden may raise the adoption rate for new treatments, which drives the growth of the market in this region. 

Asia Pacific is expected to grow substantially in the forthcoming years. This is due to the region having developed healthcare infrastructure, which increases the diagnosis and treatment rate of chronic inducible urticaria.

Key Players Covered

The global chronic inducible urticaria treatment market reflects a fragmented competitive structure with a few key players. The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Viatris Inc. (U.S.)
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Dr. Reddy’s Laboratories Ltd. (India)
• Novartis AG (Switzerland)

 Key Industry Developments

• In September 2024, Evommune, Inc. enrolled its first patient in a Phase II clinical trial of EVO756, which is designed to treat chronic inducible urticaria (CIndU) in adults. 
• In July 2024,Celldex Therapeutics, Inc. announced the positive results from the phase 2 clinical trial of the barzolvolimab, a monoclonal antibody used for the treatment of common forms of chronic inducible urticaria (CIndU), such as cold urticaria (ColdU) and symptomatic dermographism (SD).